Company Description
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis.
The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis.
In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure.
Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease.
Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.
| Country | United States |
| Founded | 2002 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 625 |
| CEO | Ying Luo |
Contact Details
Address: 12730 High Bluff Drive, Suite 250 San Diego, California 92130 United States | |
| Phone | 858-284-0115 |
| Website | gyretx.com |
Stock Details
| Ticker Symbol | GYRE |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1124105 |
| CUSIP Number | 403783103 |
| ISIN Number | US4037831033 |
| Employer ID | 56-2020050 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Ying Luo Ph.D. | Chief Executive Officer, President and Director |
| Thomas W. Eastling M.D. | Chief Financial Officer |
| Weiguo Ye | Chief Operating Officer |
| Ruoyu Chen | Chief Information Officer |
| Dr. Yue Xiong Ph.D. | Chief Scientific Officer |
| Joshua Bergmann J.D. | General Counsel and Corporate Secretary |
| Seth Goldblum M.B.A. | Senior Vice President of Corporate Development |
| Jialiang Wang Ph.D. | Executive Vice President and GM |
| Jing Liu Ph.D. | Senior Vice President of Platform Chemistry |
| Mark Marino | Senior Vice President of Clinical Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 16, 2026 | 8-K | Current Report |
| Jun 10, 2026 | S-8 | Securities to be offered to employees in employee benefit plans |
| Jun 2, 2026 | 8-K | Current Report |
| May 14, 2026 | 8-K | Current Report |
| May 12, 2026 | 8-K | Current Report |
| May 11, 2026 | 144 | Filing |
| May 8, 2026 | 10-Q | Quarterly Report |
| May 7, 2026 | SCHEDULE 13D/A | Filing |
| May 7, 2026 | 8-K | Current Report |
| May 6, 2026 | SCHEDULE 13D/A | Filing |